GlobeNewswire

Crystal Ravel Christened In Budapest

Dela

Miami, FL, July 11, 2018 (GLOBE NEWSWIRE) -- Less than two years ago, Crystal launched its first river ship, Crystal Mozart, marking the company's grand entrance into Europe's river cruising industry. Today, Crystal River Cruises welcomed its fifth ship and the newest member of the fleet, Crystal Ravel, during a christening ceremony in Budapest, Hungary. The World's Most Luxurious River Cruise Line(TM) celebrated the occasion with Crystal's President and CEO Tom Wolber; the ship's godmother, Hungarian philanthropist and creator of the hit "Virtuosos" classical music talent show, Mariann Peller; and Crystal River Cruises' Vice President and Managing Director Walter Littlejohn.

"Today is a proud day for the entire Crystal family. In just over two years, we introduced five ships, which is a tremendous accomplishment of growth for this expansion of the Crystal brand," Wolber said. "But what makes us most proud is that with each new ship and new experience, Crystal's commitment to superb quality and exceptional luxury and service has remained unwavering."

Crystal River Cruises now comprises Crystal Ravel and her identical sister ships: Crystal Bach, Crystal Mahler and Crystal Debussy; as well as Crystal Mozart, which at twice the width of any other river cruise ship, is Europe's most spacious river cruise ship and launched the brand in July 2016.

 "Beyond these exquisite ships - which are earning the acclaim of luxury travelers from around the world - the heart of the Crystal River Experience is the people," Littlejohn said. "Crystal's crew is simply unmatched in their warm, genuine service and attention to detail. Our guests are savvy travelers who truly value that personal connection and frequently share the sentiment that sailing with Crystal is like coming home to their onboard family."

"To be named the godmother of a ship that celebrates the classical musical heritage of this country and the lands that surround her - is an honor that speaks to my heart," Peller said. "Beyond the connection to the musical masters of this region, Crystal River ships represent the stunning grace, elegance and beauty of the rivers that flow here. I am honored to become part of the Crystal Family, as this company embodies a dedication to excellence."

Tenor Steffan Mullan performed during the ceremony, while Young Virtuosos artists performed aboard the ship following the traditional blessing, including clarinetist Ali Dániel Lugosi, double bassist Tamás Kökény, violinist Amira Abouzahra, violinist Mariam Abuzahra, and Budapest Festival Orchestra harpist Ágnes Polonyi with a special performance onboard the ship.

The ceremony took place during the ship's overnight stay in Budapest on its weeklong "Danube Serenade" voyage, allowing guests aboard the sailing to participate in the festivities, while Crystal crew members also looked on from the decks of the ship. Travelers from around the world joined the celebration via the Facebook Live broadcast on Crystal's Facebook page.

Crystal Ravel is currently sailing itineraries of six to 14 days between Vienna and Basel; and in 2019 she will be the only river ship to sail seven-night Danube cruises round-trip from Vienna to ports in Austria, Hungary and Slovakia.

Crystal's new river vessels are the river cruising industry's first and only all-balcony, all-suite, all-butler vessels in Europe, with every category of accommodation positioned above the water line.  All suites feature Panoramic Balcony-Windows(TM) and walk-in closets and dual vanity in the bathrooms are featured in most categories. Crystal Mozart is Europe's most spacious river ship, at twice the width of any other, and offers an unrivalled number of social spaces, restaurants and the largest spa on the rivers. All of Crystal's river ships feature acclaimed butler service in every room category, king-sized beds, ETRO amenities, robes and slippers, and wall-mounted flat-screen HD TVs. Additional enticing features include farm-to-table cuisine in multiple, open-seating eateries: the elegant Waterside Restaurant, namesake Bistro cafés and the exclusive Vintage Room; and the Palm Court for entertainment, enrichment presentations and sweeping views of the countryside.

About Crystal

The world-renowned Crystal Experience - featuring global journeys with Crystal Cruises, Crystal River Cruises, Crystal Yacht Expedition Cruises, Crystal AirCruises and Crystal Luxury Air - continues to be the distinctive choice of the world's most discerning travelers. Crystal Cruises is the World's Most Awarded Luxury Cruise Line, having earned "World's Best Cruise Ship" in Condé Nast Traveler's Reader Choice Awards and been voted "World's Best Large Ship Cruise Line" by Travel + Leisure readers more than any cruise line, hotel or resort in history; and the "Best Luxury Cruise Line" by travel professional organization Virtuoso for three consecutive years (2014, 2015 & 2016). The readers of Travel + Leisure also voted Crystal River Cruises the "World's Best River Cruise Line" and Crystal Yacht Expedition Cruises the "World's Best Small-Ship Cruise Line" in 2017. Crystal is proud to be a platinum partner of ASTA.

For more information and Crystal reservations, contact a travel professional, call 888.799.2437, or visit www.crystalcruises.com. Join the hundreds of thousands who subscribe to the Crystal Insider blog, follow Crystal Cruises' Facebook page and @crystalcruises on Twitter and Instagram, and engage in the conversation with #crystalcruises.

###

Attachments

Media Relations
Crystal Cruises
3102034305
mediarelations@crystalcruises.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crystal Cruises via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum